The Dockrell group is examining vaccine - induced immune responses that may predict immune
protection against tuberculosis (TB), and how co-infection and co-morbidity can affect such immune responses.
Not exact matches
Studies in several countries have demonstrated that the
tuberculosis vaccine BCG, when given early in life, confers some
protection against acute leukaemia (Journal of the Royal Society of Medicine, vol 96, p 389).
Protection against subsequent
tuberculosis challenge was greater with the DAR - 901 booster than with the BCG booster.
Then the researchers zeroed in on a gene variant that offers
protection against diseases like
tuberculosis or leprosy.
Similar to these projects, IDRI's subunit
tuberculosis vaccine, ID93, also utilizes adjuvants that induce a cell - mediated immune response, which is required for
protection against M.
tuberculosis infection in low dose aerosol models of TB.